APOE and Human
Cognosci Selected to Present at CED's Venture 2007 Conference
Company to showcase drug leads to treat Multiple Sclerosis
RESEARCH TRIANGLE PARK, N.C., April 9, 2007 - Cognosci, Inc., an established pharmaceutical company with proprietary anti-inflammatory compounds based on apolipoprotein-E, announced today that it has been selected as an Early Stage presenting company at the Venture 2007 Conference sponsored by the Council for Entrepreneurial Development (CED) on April 23-25, 2007, in Durham, N.C. Cognosci's presentation will be at 5:25 pm on April 24th.
"Cognosci is proud to be selected to present at Venture 2007 as a first step towards raising the funds necessary to progressing our programs into clinical trials" said Dr. Michael P. Vitek, Cognosci's Founder and President. "To date we have focused our efforts on developing our
technology and we are now poised to raise our Series A round of institutional investment so that we can proceed with clinical development of our compounds to treat debilitating and life threatening diseases."
"CED has selected promising high growth companies from an array of industries that are looking to raise either initial or subsequent rounds of professional equity capital," said Robert Albright, CED's communications director. "That Cognosci has collected over $7.5 million in SBIR funds validates the rigor of the company's scientific programs, and we are excited to include them as they seek their first round of Venture Capital investment."
Venture 2007, scheduled for April 23-25 at the Washington Duke Inn in Durham, NC, is the Southeast's premier venture financing conference. Presented by CED with support from the Research Triangle Park and the National Venture Capital Association, Venture 2007 will continue a 24-year tradition of showcasing the Southeast and Mid-Atlantic's top investment opportunities to hundreds of venture capitalists and financiers from throughout the United States. Since 2001, Venture presenters have raised over $1.2 billion in venture capital. In addition to
company presentations, Venture 2007 (www.cednc.org/venture) will include leading industry speakers, extensive networking opportunities and exclusive investor-only events.
About Cognosci, Inc.
Cognosci Inc. was founded in May 2000 to develop anti-inflammatory and neuro-restorative compounds for therapuetic treatment of neurodegnerative diseases such as Multiple Sclerosis, Alzheimer's Disease, and Traumatic Brain Injuries. Each of these disorders has a
pharmacogenomic linkage to apolipoprotein-E gene and patients carrying the å4 allele of the APOE gene typically suffer worse outcomes. Cognosci scientists have created novel apoE-based compounds with potent anti-inflammatory and neuroprotective activities that are in preclinical development for the treatment of multiple sclerosis and other degenerative indications.
The Council for Entrepreneurial Development, located in Research Triangle Park, NC, is a private, non-profit organization formed in 1984 to stimulate the creation and growth of highimpact companies in the greater Research Triangle region. CED provides education, mentoring and capital formation resources to new and existing high-growth entrepreneurs through annual conferences, seminars, workshops and monthly programs on entrepreneurial management and finance. CED is the largest entrepreneurial support organization in the nation with more than 4,000 members representing 1,100 entrepreneurial companies, financiers and professional firms. www.cednc.org
Source: Cognosci, Inc.
Contact: Dale Christensen, Ph.D.
VP of Business Development
Cognosci Receives Funding for Advanced Testing of Lead Drug Candidate for the Treatment of Multiple Sclerosis
For more information, contact:
2 Davis Drive
Research Triangle Park